clinicalprofessionals.co.uk
AstraZeneca’s treatment cuts cardiovascular risks in diabetes patients - Clinical Professionals
Trial data has shown that AZ’s Dapagliflozin cut risk of major adverse cardiovascular events in patients with type II diabetes who had a prior heart attack.